Showing results (181-190 of 206) with videos related to
Sort By:
Pageof 21
Veterinary Microbiology|September 1, 2022
ATG4B hinders porcine epidemic diarrhea virus replication through interacting with TRAF3 and activating type-I IFN signalingSujie Dong, Ning Kong, Wenzhen Qin, et al.Clinical Rheumatology|May 17, 2025
BAricitinib in patients with SystemIC Sclerosis (BASICS): a prospective, open-label, randomised trialFangfang Chen, Wenjing Ye, Qian Wang, et al.International Immunopharmacology|March 12, 2025
Aging and autophagic phenotypic changes in bone marrow mesenchymal stem cells in glucocorticoid-induced osteonecrosisRuomu Cao, Heng Li, Guanzhi Liu, et al.Advanced Materials (Deerfield Beach, Fla.)|May 12, 2020
Cobalt Plasmonic Superstructures Enable Almost 100% Broadband Photon Efficient CO2 PhotocatalysisKai Feng, Shenghua Wang, Dake Zhang, et al.Journal of Virology|December 21, 2022
PRPF19 Limits Porcine Epidemic Diarrhea Virus Replication through Targeting and Degrading Viral Capsid ProteinXueying Zhai, Ning Kong, Chunmei Wang, et al.Microbiology Spectrum|October 6, 2021
PABPC4 Broadly Inhibits Coronavirus Replication by Degrading Nucleocapsid Protein through Selective AutophagyYajuan Jiao, Ning Kong, Hua Wang, et al.Frontiers in Neuroscience|April 3, 2023
Traditional Chinese Manual Therapy (Tuina) reshape the function of default mode network in patients with lumbar disc herniationXiao-Min Chen, Ya Wen, Shao Chen, et al.Current Issues in Molecular Biology|February 23, 2024
An Expeditious Neutralization Assay for Porcine Reproductive and Respiratory Syndrome Virus Based on a Recombinant Virus Expressing Green Fluorescent ProteinJuan Wang, Jiecong Yan, Shuaiyong Wang, et al.The Journal of Biological Chemistry|June 26, 2022
Nuclear ribonucleoprotein RALY targets virus nucleocapsid protein and induces autophagy to restrict porcine epidemic diarrhea virus replicationWenzhen Qin, Ning Kong, Yu Zhang, et al.Rheumatology and Therapy|August 20, 2025
Efficacy and Safety of Firsekibart Compared to Etoricoxib for Gout Flares: A Phase 2, Multicenter, Open-label, Active-controlled, Randomized Non-inferiority TrialNing Kong, Yu Xue, Li Mao, et al.Pageof 21